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Abstract
Background: In asthma, mechanisms contributing to chronicity remain to be determined. Recent models of sensitisation
with prolonged airway allergen challenges reproduce typical features of chronic asthma. However, the interplay between
inflammation, structural changes and lung function is poorly understood. This study was performed to delineate functional,
structural and immunological airway changes after cessation of long term challenges to elucidate factors contributing to the
development of prolonged lung function changes.
Methodology/Principal Findings: Mice sensitised systemically were consecutively challenged intranasally with ovalbumin
for two or eight weeks. After the end of challenges, lung function, airway inflammation, features of airway remodelling, local
T-cell cytokines and systemic ovalbumin-specific antibodies were monitored. Long term challenges resulted in airway
hyperresponsiveness lasting 2 weeks and reduced baseline lung function for 6 weeks after their cessation. In contrast, these
changes resolved within one week after short term challenges. Prolonged transforming growth factor beta (TGF-b)1
production and marked peribronchial fibrosis were only induced by long term challenges. Importantly, fibrosis became
apparent only after the onset of lung function changes and outlasted them. Further, long term challenges led to prolonged
and intense airway inflammation with marked lymphocytosis, but moderate eosinophilia, sustained IL-5 production and
ovalbumin-specific IgG2a antibodies, the latter suggesting a Th1 component to the immune response. In contrast, following
short term challenges airway inflammation was dominated by eosinophils and associated with a strong, but transient IL-13
response.
Conclusions: Prolonged lung function changes after long term allergen challenges seem to develop and resolve
independently of the persistent peribronchial fibrosis. They are more closely associated with intense airway inflammation,
marked lymphocytosis, prolonged IL-5 and TGF-b1 production in the airways and a Th1 immune response.
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Introduction
Asthma now affects more than 10% of children in industrialized
countries [1] and results in considerable morbidity and mortality.
Current asthma management does not prevent chronic disease.
We therefore need to understand the pathogenic mechanisms
leading to chronicity. Defining the impact of chronic structural
changes on lung function is of particular interest.
Mouse models of allergic airway sensitisation with short term
allergen challenges have elucidated mechanisms of acute inflam-
matory and functional responses like airway eosinophilia and
transient airway hyperresponsiveness (AHR) (reviewed by Kumar
[2]) but failed to induce characteristic features of chronic asthma,
such as airway wall remodelling, including sub-epithelial fibrosis
[3] and muscular hypertrophy [4], and long term changes in lung
function, all of which can be seen in models with prolonged airway
challenges [5–14]. However, the protocols employed vary
significantly, and only few of the long term studies investigated
the persistence of changes after final allergen contact yielding
conflicting results especially regarding persistence of impaired lung
function [5,9,13]. Thus, the nature of interactions between airway
remodelling and impaired lung function remains poorly defined.
Predominance of Th2 cytokines in murine models of acute
allergic airway inflammation is well established [15] and important
roles of IL-5 in induction of airway eosinophilia and of IL-5, IL-4
and IL-13 in the development of AHR [16,17] have been defined.
More recently, profibrotic roles for IL-13 and IL-4 [18,19] in
airway remodelling have emerged. Data comparing T-cell
responses between models with short term and chronic allergen
challenges are scarce. In atopic dermatitis, a shift from an initial
Th2 response to a Th1 response in chronic disease has been
reported [20]. There is also some evidence supporting a
contribution of Th1 cytokines to the immune response in severe
human asthma [21,22]. Interestingly, evidence of Th1 responses
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with IFN-c production has also been found recently in a murine
model of chronic airway sensitisation [9].
Here, we report a sensitisation model with long term airway
allergen challenges which induce typical features of chronic
asthma including protracted changes in lung function, airway
inflammation, mucus hyperplasia and peribronchial fibrosis. To
delineate factors contributing to these chronic changes we
compared immunological, functional and structural consequences
after the cessation of long and short term challenges.
Materials and Methods
Animals
Female BALB/c mice, 6–8 weeks of age, from Charles River
Deutschland (Sulzfeld, Germany) were used under protocols
approved by Regierungspra¨sidium Arnsberg (NRW, Germany).
Experimental protocol
Mice were sensitised on days 1 and 7 by intraperitoneal
injection of 20 mg ovalbumin (OVA) (Sigma-Aldrich, Taufkirchen,
Germany) emulsified in 2.25 mg aluminium hydroxide (AlumI-
muject; Pierce, Rockford, Ill) in 100 ml. Mice were challenged
intranasally with 40 ml of 1% OVA in PBS under light anaesthesia
with xylazine (BayerVital, Leverkusen, Germany)/ketamine (Cur-
aMED Pharma, Karlsruhe, Germany). Controls were treated
intraperitoneally with PBS, emulsified in aluminium hydroxide,
and intranasally with sterile PBS. Two different challenge
protocols were used: once weekly airway challenges for 2 weeks
(short term) or for 8 weeks (long term). 48 hours, 2, 4, and 8 weeks
after the final airway challenge lung function was determined.
24 hours after lung function tests, mice were sacrificed for harvest
of bronchoalveolar lavage (BAL) fluid, lungs and serum. Blood was
drawn by tail vein puncture prior to cervical dislocation.
Lung function measurements
Baseline lung function and airway responsiveness to increasing
concentrations of methacholine (MCh) (Sigma-Aldrich) were
assessed using a single-chamber, whole-body plethysmograph
(Buxco Electronics Inc, Troy, New York, USA) as described
[23]. Briefly, unrestrained, spontaneously breathing mice were
placed in plethysmographs and challenged with aerosols of PBS
and increasing concentrations of MCh. At baseline after PBS-
exposure and following each provocation, enhanced pause (Penh)
values were monitored for 4 min.
Lung histology
Lungs were fixed with 4% paraformaldehyde prior to embedding
in paraffin. 5 mm sections were stained with haematoxylin/eosin to
assess inflammatory infiltrates, with Alcian Blue Periodic Acid -
Schiff (PAS) to detect mucin in goblet cells, and with Masson’s
trichrome to determine the amount of peribronchial collagen (all
dyes from Merck, Darmstadt, Germany). Sections were analysed
using a Zeiss Axioplan 2 imaging microscope, Axiocam camera and
Axiovision 4.3 software (Zeiss, Jena, Germany). Airway inflamma-
tion was quantified in the peribronchial region of 6–8 different
medium-sized bronchi per slide at620 magnification, using a semi-
quantitative scoring system with a grading scale from 0 (no
inflammation) to 4 (very severe inflammation). Goblet cell
hyperplasia was determined by enumerating PAS-positive cells in
airway epithelium at640 magnification. Collagen deposition (green
stain) was quantified in peribronchial areas in sections stained with
Masson’s trichrome using AnalySis 3.2 software (Software Imaging
Systems, Mu¨nster, Germany) by determining the ratio of green area
per total tissue/matrix area (green/100-non-stained).
Assessment of BAL inflammatory cells
Total leukocyte numbers in the BAL fluid were counted in a
Neubauer chamber. Following cyto-centrifugation (Cytospin,
Shandon Inc., Pittsburgh, PA) and staining with Haema
Schnellfa¨rbelo¨sung, (Labor und Technik, Eberhard Lehmann,
Berlin, Germany), at least 300 cells per slide were differentiated by
a blinded investigator using standard haematological criteria.
Measurement of cytokines in BAL fluid
Cytokine levels in BAL fluid were measured by ELISA for IL-4,
IL-10 and IL-12 (OptEIA, Becton Dickinson, Heidelberg,
Germany) as well as for IL-13 and activated TGF-b1 (Quantikine
Sandwich ELISA, R&D Systems, Wiesbaden, Germany) accord-
ing to the manufacturer’s directions. In IL-5 and IFNc ELISA the
following antibodies were used: Purified rat anti-mouse IL-5
(TRFK5) for coating and biotin rat anti-mouse IL-5 (TRFK4) for
detection, and rat anti-mouse IFNc (XMG1.2) purified and
biotinidated for coating and detection (all Pharmingen, Becton
Dickinson, Heidelberg, Germany). The detection limits were
7 pg/ml for IL-4, 15 pg/ml for IL-5, 8pg/ml for IL-10, 80 pg/ml
for IL-12p70, 5 pg/ml for IL-13, 20 pg/ml for IFNc and 30pg/ml
for activated TGF-b1.
Flow cytometry
Lungs were minced, digested with collagenase (Sigma-Aldrich)
for 30 min, and washed. Mononuclear cells were isolated by Ficoll
(Biochrom AG, Berlin, Germany) gradient. For intracellular
cytokine staining, lung cells were stimulated for 4 hours with
PMA (30 ng/ml), and ionomycin (300 ng/ml) in the presence of
brefeldin A (10 mg/ml) (all from Sigma-Aldrich). Following
fixation and permeabilization, cells were stained with the
appropriate antibodies or isotype controls. A FACScan analyser
(Becton Dickinson) was used for data acquisition and Cellquest
software (Becton Dickinson) for analysis. The following antibodies
(all Becton Dickinson) were used: anti-CD3 (145-2C11) FITC-
conjugated; anti-IL-4 (11B11), anti-IL-5 (TRFK5), and anti-IFNc
(XMG1.2) PE-conjugated, rat IgG2a (R35-95), rat IgG2b (A95-1),
rat IgG1 (R3-34), mouse IgG2b (MPC-11) and hamster IgG (A19-
3) were used as isotype controls.
Measurement of OVA-specific antibodies in the serum
Serum levels of OVA-specific IgE, IgG1, and IgG2a were
measured by ELISA as described. Briefly, 96-well-plates (Greiner
bio-one, Frickenhausen, Germany) were coated with OVA (5 mg/
ml) (Sigma-Aldrich) in carbonate buffer and washed. Then serum
samples were added and plates were washed again. For IgE
detection, biotinylated anti-IgE antibody (R35-72, Becton Dick-
inson) was used with extravidin-POD (Sigma-Aldrich) and TMB
as substrate. OVA-specific IgG1 and IgG2a were detected with
alkaline phosphatase-labeled anti-IgG1 (X56) or anti-IgG2a (R19-
15) antibodies (both Becton Dickinson) respectively and pNPP
substrate (Sigma-Aldrich). OVA-specific antibody titres were
related to an internal, pooled standard and expressed as internal
units (IU)/ml. The detection limit for OVA-specific IgE was
2,0 IU/ml, for OVA-specific IgG1 and –IgG2a 0,001 IU/ml.
Statistical analysis
Data were compared using GraphPad Prism 4.02 (GraphPad
Software, San Diego, USA). Mann-Whitney test was used for
comparison of 2 groups and Kruskal-Wallis test with Dunn post
hoc test were used for comparisons of more than 2 groups. P
values for significance were set at 0.05 except for flow cytometry
data and Penh data where p values of ,0.01 were regarded as
Murine Model of Chronic Asthma
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Following short term as well as long term OVA challenges in
OVA sensitised mice, AHR of comparable magnitude developed.
48 hours after the last challenge maximal Penh values at 50 mg/
ml MCh were 7.3860.72 and 6.7460.37 for long term and short
term challenges respectively, compared to 3.9660.26 in PBS
challenged controls. After short term challenges AHR resolved
within one week, while it persisted for 2 weeks after long term
challenges (Fig 1a). In addition, baseline Penh values in the
absence of provocation were significantly increased 48 hours after
OVA challenges in both treatment groups compared to mice
challenged with PBS (Fig 1b). Interestingly, in contrast to AHR,
baseline Penh values remained elevated for up to 6 weeks
following long term challenges, while they normalised within a
week after short term challenges (Fig 1b).
Airway inflammation
Both short and long term airway OVA challenges induced
marked airway inflammation (Fig 2d, m). Inflammation was more
severe after long term than after short term challenges, with
respective scores of 3.4360.14 and 2.6860.09, p,0.05, n= 6 per
group. PBS challenged mice did not develop airway inflammation
(average score 0.12560.06, Fig 2a). All visible airways were
affected by inflammation in all OVA challenged animals.
Parenchymal inflammation was not detected in any of the groups.
Over time, airway inflammation declined, but did not resolve
completely by 8 weeks after the final challenge irrespective of the
protocol used (Fig 2j, s).
To characterise the quality of airway inflammation, BAL cells
were analysed. 72 hours after the final challenge total cell numbers
in BAL fluid were raised 6–10 fold compared to control mice
without significant differences between the two challenge protocols
(PBS: 124,900618,300 cells/ml, short term OVA:
*1,081,1006244,900, long term OVA: *841,800690,200,
*p,0.05 versus PBS, n$10). BAL cell numbers remained
significantly elevated (3-fold over controls) until 8 weeks after the
final challenge following long term challenges, whereas they
returned to baseline within 2 weeks following short term
challenges (data not shown). OVA challenges resulted in
eosinophilia and lymphocytosis in BAL fluid, but with striking
differences between protocols (Fig 3a, b). Short term challenges
resulted in very strong eosinophilia accounting for 60–70% of total
BAL cells and moderate lymphocytosis representing 9% of BAL
cells. In contrast, long term challenges induced marked lympho-
cytosis accounting for 27% of BAL cells, accompanied by
moderate eosinophilia of 24% of BAL cells. Following both
challenge protocols BAL eosinophilia resolved after 2 weeks, while
numbers of lymphocytes decreased over time but remained
significantly elevated for 4 weeks after short term and for 8 weeks
after long term challenges.
Goblet cell hyperplasia
OVA challenges in both protocols resulted in pronounced goblet
cell hyperplasia 72 hours after final challenges (Fig 2e, n). Airways of
PBS challenged controls did not contain PAS positive goblet cells
(Fig 2b). Marked goblet cell hyperplasia was still evident 4 weeks
after long term challenges (Fig 2q), but was reduced in mice
challenged over 2 weeks only (Fig 2h). By 8 weeks after challenges
goblet cell hyperplasia had resolved in both groups (Fig 2k, t).
Peribronchial collagen deposition
Increased airway collagen deposition, a typical feature of airway
remodelling in chronic asthma, was assessed peribronchially
comparing long term to short term airway challenges. By 4 weeks
after long term OVA challenges the collagen matrix around the
bronchi was increased 2 to 3-fold to *8.164.1% (n= 9, *p,0.05)
(Fig.2r) compared to short term challenges (3.162.4%) (Fig 2 f,i,l)
and PBS controls (4.561.9%) (Fig 2c) and remained elevated until
week 8 (*7.463.6) (Fig 2u). Notably, increases in collagen
deposition did not develop immediately after long term challenges
(3.661.8) (Fig 2o).
Airway cytokine responses
Th2 cytokines (IL-4, IL-5 and IL-13), which dominate many
murine models of short term airway sensitisation, Th1cytokines
(IFN-c and IL-12), as well as IL-10, a cytokine associated with
regulatory immune responses, were measured in BAL fluid by
ELISA. Both short and long term OVA challenges induced
Figure 1. Lung function following long and short term airway
challenges. (a) Following OVA sensitisation and short or long term
OVA challenges or after sham sensitisation and long or short term PBS
challenges, airway responsiveness to MCh was assessed 48 hours after
final airway challenge and then weekly for 8 weeks. Mean6SEM of Penh
values at 50 mg/ml MCh are shown for the first 4 weeks only from 3
independent experiments (n$12). No differences between groups were
detected after week 4. (b) Baseline Penh values were assessed during
the same measurements. Mean6SEM from 5 independent experiments
are illustrated (n$15). Significant differences: * long term OVA
challenges versus PBS control, +short term OVA challenges versus PBS
control, levels of significance: */+ p,0,01, **/++ p,0,001.
doi:10.1371/journal.pone.0001575.g001
Murine Model of Chronic Asthma
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increased levels of IL-5 and IL-13, however with marked
differences between the two protocols (Fig 4a, b). Three days
after final challenges, IL-13 dominated the response to short term
challenges, while IL-5 was the dominant cytokine induced by
prolonged challenges. IL-13 rapidly fell to undetectable levels by
2 weeks after challenges regardless of the protocol. IL-5 levels in
contrast, persisted and even rose further 4 weeks after the final
challenge in the long term challenge protocol, whereas the small
increases in IL-5 after short term challenges were transient. IL-4
was only detected in minimal levels in both challenge protocols
(data not shown). In addition to the Th2 cytokines, IFN-c (up to
540 pg/ml) was induced 4 weeks after long term challenges in
25% of mice. This response failed to reach statistical significance,
but IFN-c was never detected after short term challenges. There
were no significant changes in IL-10 and IL-12 levels in BAL fluid
between challenge protocols (data not shown).
In addition, we assessed intracellular cytokines in lung
mononuclear cells. Four weeks after long term but not short term
challenges, percentages of IFN-c producing lung cells
(5.3160.45%) were significantly elevated compared to long term
PBS controls (3.6460.55%, p,0.01, n = 10, 2 independent
experiments). Similar differences 3 days and 2 weeks after long
term challenges did not reach significance. Further, the percentage
of IL-5 producing lung cells were significantly elevated following
OVA challenges compared to PBS challenged controls and IL-5
producing lung cells were significantly more common three days
and two weeks after long term OVA challenges (5.4360.72% and
5.7860.36%, p,0.01, n= 10) than after short term exposure
(3.7660.44% and 3.2860.29%, both n= 10). IL-4+ lung cells
were detectable after OVA challenges but there were no
differences between protocols (data not shown).
TGF-b1 in BAL fluid
In addition to the cytokines mentioned above we also assessed
BAL levels of activated TGF-b1, a cytokine involved in the
development of fibrosis. TGF-b1 was not detectable in control
mice, but was markedly elevated 3 days after both short and long
term challenges (Fig 4a). Following short term challenges, TGF-b1
Figure 2. Airway inflammation, goblet cell hyperplasia and
airway fibrosis following long and short term OVA challenges.
Representative photomicrographs of paraffin-embedded lung sections
stained with H&E (left column), Alcian-PAS (middle column) and
Masson’s trichrome (right column) from short term OVA challenged
animals (d–l), long term OVA challenged animals (m–u) and after PBS
treatment (a–c) 3 days (row 2 and 5), 4 weeks (row 3 and 6) and
8 weeks (row 4 and 7) after challenges. Magnification: 20-fold for H&E,
20-fold for Masson’s trichrome, and 40-fold for Alcian-PAS stained
sections.
doi:10.1371/journal.pone.0001575.g002
Figure 3. Eosinophils and lymphocytes in BAL fluid after long
and short term airway challenges. Following OVA sensitisation and
short or long term OVA challenges or after sham sensitisation and long
or short term PBS challenges, numbers of (a) eosinophils, and (b)
lymphocytes were determined in BAL fluid from 3 days to 8 weeks after
final airway challenge, n$12 per group from 5 independent experi-
ments. Significant differences: * OVA challenges versus PBS controls,
+long term versus short term OVA challenges, */+ p,0,05, **/++ p,
0,01, ***/+++ p,0,001.
doi:10.1371/journal.pone.0001575.g003
Murine Model of Chronic Asthma
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levels declined quickly and became undetectable within 4 weeks.
In contrast, after long term challenges TGF-b1 levels declined to a
lesser degree and were still significantly increased 4 weeks after
challenges and still detectable at 8 weeks.
OVA-specific serum antibodies
Systemic OVA sensitisation with consecutive OVA challenges
induced OVA-specific IgE in serum without significant differences
between long and short term challenges (Table 1). OVA-specific
IgG1 levels were initially significantly higher following long term
challenges, but they reached comparable levels within 2 weeks
after short term challenges. In addition to these antibodies which
are associated with Th2 responses, prolonged airway challenges
also induced robust production of OVA-specific IgG2a, an
antibody found in Th1 responses. IgG2a was detectable from
3 days after challenges and throughout the 8 weeks of observation.
In contrast, following short term challenges, OVA-specific IgG2a
was only detected in significant amounts 8 weeks after challenges.
Discussion
The pathogenic mechanisms involved in the development of
chronicity in asthma are poorly understood. Recently established
murine models of allergen sensitisation followed by long term
allergen challenges do not only lead to impaired lung function
(similar to short term challenge models) but also to airway wall
remodelling, a feature typical of chronic asthma. Only a few of
these studies investigated the duration of changes after the end of
challenges and yielded conflicting results [5,9,13]. Using a murine
model of systemic allergen sensitisation we compared the
consequences of short and long term airway allergen challenges
during eight subsequent weeks, monitoring lung function, airway
inflammation, features of airway wall remodelling and immune
responses.
Lung function impairment with airflow limitation is thought to be
the most threatening consequence of severe asthma. It is therefore of
major importance to identify mechanisms involved in the
development of chronically impaired lung function. In the present
model, AHR was only short lived after cessation of challenges as
observed previously [9]. Recently, it has been demonstrated that
AHR is sustained and even progressive while chronic allergen
challenges are ongoing[12,13]. However, persistent AHR during
8 weeks after prolonged challenges has been detected only in one
model when pulmonary resistance was assessed in anaesthetised and
ventilated mice challenged with MCh intravenously [5]. In addition
to AHR, we observed increases in baseline Penh values early after
both short and long term challenges. These resolved quickly after
short term challenges, but only after 6 weeks post long term
challenges. Such increases in baseline Penh, which reflect increased
respiratory effort, have previously been described in mice as short
lived, asthmatic late phase responses arising within hours after
challenges [24]. Measuring mid-expiratory airflow in unprovoked
mice, deterioration of baseline lung function has been shown during
ongoing allergen challenges [13], but not after challenges as in our
study.
Increases in airway collagen deposition, are thought to
contribute to the development of chronic lung function impair-
ment. This notion was supported by a report from a chronic
asthma model that depletion of T-cells did not abrogate AHR
[25]. The authors suggested that AHR in chronic allergen
exposure is a consequence of remodelling with airway narrowing
rather than of cellular inflammation. However, assessing the
temporal relationship between lung function changes and collagen
deposition in our study, it is striking that both AHR and reduced
baseline lung function were evident before the onset of
peribronchial fibrosis and that they resolved despite its persistence.
This indicates that the lung function changes observed here are
neither dependent on the presence of airway wall fibrosis, nor does
the latter necessarily result in lung function changes. This raises
the question if airway wall fibrosis is irrelevant for lung function or
even if fibrosis provides a protective mechanism in asthma
contributing to airway patency rather than to airflow limitation.
Figure 4. Cytokines in BAL fluid after long and short term
airway challenges. Following OVA sensitisation and short or long
term OVA challenges or after sham sensitisation and long or short term
PBS challenges, concentrations of (a) IL-5, (b) IL-13 and (c) activated
TGF-b1were measured in BAL fluid by ELISA 3 days to 8 weeks after
final airway challenge, n$15 per group from 5 independent experi-
ments. Significant differences: * OVA challenges versus PBS controls,
+long term versus short term OVA challenges, */+ p,0.05, **/++ p,
0.01, ***/+++ p,0.001.
doi:10.1371/journal.pone.0001575.g004
Murine Model of Chronic Asthma
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Goblet cell hyperplasia, another feature of airway wall
remodelling, developed during challenges and thus might play a
role in the induction of lung function changes. However, AHR
resolved when goblet cell hyperplasia was still marked suggesting
that mucus overproduction does not necessarily result in AHR.
Interestingly, goblet cell hyperplasia and baseline lung function
changes resolved around the same time between 4 and 8 weeks
after long term challenges, suggesting a possible link.
Airway allergen challenges induced long lasting airway inflam-
mation in our model with striking differences depending on the
duration of challenges. Sustained airway lymphocytosis and
moderate, short lived eosinophilia were induced by long term
challenges, while short term challenges resulted in marked
eosinophilia which resolved after 2 weeks. The extent of airway
eosinophilia has been related to the degree of AHR in asthmatics
[26,27] and in murine models (reviewed by Hamelmann [28]). Our
observations that AHR and airway eosinophilia were both of
transient nature irrespective of challenge protocol support this
notion. On the other hand, baseline lung function changes persisted
in our model in the absence of eosinophilia, suggesting that these
longer lasting changes are independent of eosinophilic inflammation.
The Th2 cytokines IL-5 and IL-13 have been implicated in the
development of AHR in many models of short term allergen
challenges. Following long term challenges we found persistent IL-5
production in the airways and low, transient levels of IL-13. In
contrast, short term challenges were associated with strong but
transient IL-13 production and low levels of IL-5. Predominant IL-
13 production after short term, but not after prolonged challenges
has been seen in similar models of OVA sensitisation [5,9].
However, sensitisation to house dust mite induced expression of
both IL-13 and IL-5 for several weeks after prolonged challenges
[29]. In contrast toMcMillan and colleagues [9], we and others [13]
failed to detected IL-4 expression after long term challenges. Recent
models of chronic airway allergen exposure demonstrated that the
lack of IL-5 did not affect collagen deposition or AHR [18], while
inhibiting BAL eosinophilia completely. IL-13 depletion prevents
the development of AHR following short term challenges [30], but
not in a seperate chronic asthma model, while suppressing
eosinophilia and some features of remodelling [31]. These findings
suggest that while Th2 cytokines may be involved in establishing
airway dysfunction, they are not needed to maintain it.
In addition to Th2 responses, Th1 cytokines have been detected
in severe asthma [21,22]. In our model, a discrete transient IFN-c
response was observed in some animals 4 weeks after long term
challenges, in keeping with a similar published observation [9]. The
notion that Th2 and Th1 responses coexist after long term allergen
challenges is strengthened further by the detection of OVA-specific
IgG2a antibodies in addition to specific IgE and IgG1 antibodies in
our study. IgG2a antibodies, which are associated with Th1
immune responses in the mouse, were not detected following short
term challenges. Th1 responses presumably contribute to inflam-
mation, airway remodelling and lung function changes following
prolonged allergen challenges, considering that Th1 cells do not
protect against allergic airway inflammation [32]. Further, IFN-c
depletion has been reported to diminish AHR and inflammatory
cell accumulation in a chronic asthma model, but did not influence
remodelling and eosinophil influx [31]. While the precise role of
Th1 responses in chronic asthma remains to be determined, it seems
that the immunology of chronic allergic airway inflammation is
complex and that therapeutic strategies focussing on single cytokines
only cannot be (and have not been) successful. Detrimental effects of
both Th1 and Th2 responses may be antagonized by regulatory T
cells, which have been shown to reduce allergen-induced AHR and
inflammation in mice [33].
TGF-b1, a cytokine known to induce fibrosis, is produced by a
range of airway and immune cells including a subset of regulatory T
cells [34]. In our study, sustained production of TGF-b1 in the
airways for up to 8 weeks after long term challenges was associated
with sub-epithelial fibrosis. Marked TGF-b1 production has
previously been seen during but not beyond long term OVA
challenges in mice [9,13]. In asthmatics, increases in airway TGF-
b1 levels have also been demonstrated [35,36], and TGF-b1
induces collagen synthesis in bronchial fibroblasts and transforms
them to myofibroblasts [37,38]. Considering these findings it seems
likely that TGF-b1, induced by persistent airway inflammation, is
an important profibrotic factor following chronic allergen exposure.
In summary, we report a mouse model of sensitisation followed
by long term allergen challenges leading to sustained allergic
airway inflammation, goblet cell hyperplasia, peribronchial
fibrosis, and impaired lung function. The sequence in which these
features arise and resolve suggests that airway wall fibrosis may not
contribute to lung function impairment. The marked differences in
the quality of airway inflammation and immune responses after
long and short term allergen challenges may help to elucidate
mechanisms responsible for chronic functional and structural
changes in asthma.
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Table 1. OVA specific serum antibodies following sensitisation and short or long term challenges
Short term OVA challenges Long term OVA challenges
Time post challenge IgE [IU/ml] IgG1 [IU/ml] IgG2a [IU/ml] IgE [IU/ml] IgG1 [IU/ml] IgG2a [IU/ml]
3 days 90615*** 34.6611.7** 0.0060.00 210678* 373.9696.7**/++ 72.18637.14*/+
2 weeks 37610** 310.6673.9** 0.0160.01 60616** 433.5691.8** 18.3969.20*/+
4 weeks 56613*** 138.4664.5 4.6664.40 96639* 254.5651.2*** 21.6610.11*/+
8 weeks 112658* 92.2657.3 40.03611.52* 102647* 238.4663.9*** 130.10639.85**/+
Serum concentrations of OVA-specific antibodies post challenges were assessed by ELISA. In PBS controls no OVA-specific IgG1 or IgG2a was detected and there was a
background of OVA-specific IgE of maximally 1.0 IU/ml. Significant differences: *versus respective PBS control, +versus respective time point after short term OVA
challenges, */+ p,0.05, **/++ p,0.01, ***/+++ p,0,001. Means6SEM are shown, n$9 from 3 independent experiments.
doi:10.1371/journal.pone.0001575.t001
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